Bausch & Lomb: Alrex

The first corticosteroid specifically designed for seasonal allergic conjunctivitis, Alrex^® offers powerful relief against the whole symptom complex, i.e., itching, redness, burning, and photophobia.

Relief begins approximately within two hours after installation of Alrex,¹ with dramatic improvement over the two-week treatment period. Alrex offers safety comparable to placebo with minimal risk of IOP rise.^{2, 3}

Alrex was one of the fastest growing prescription medications for Seasonal Allergic Conjunctivitis in the ocular allergy market for 1999.⁴

	Key Benefits		Contraindications
	Package Insert

Relieves whole symptom complex of allergic conjunctivitis

Fast acting (2 hours)

Predictable transformation into inactive metabolite²

Low incidence of adverse events²

Broad relief across the entire inflammatory cascade

As with other ophthalmic corticosteroids, Alrex is contraindicated in most viral diseases of the corneas and conjunctiva and in mycobacterial and fungal diseases of the eye. Prolonged use of corticosteroids may result in secondary glaucoma, cataract formation, and secondary ocular infections following suppression of the host response and/or perforation of the globe. The most common adverse events in patients treated with Alrex were abnormal vision/blurring, burning, chemosis, discharge, and dry eyes.







					Build your practice. Create your own Web page. We've even prepared a sample to give you some ideas.


	¹ Alrex^® [package insert]. Tampa, Fla: Bausch & Lomb Pharmaceuticals, Inc.; 1998. ² Schulman DG et al. Ophthalmology. 1999;1006:362-369. ³ Dell SJ et al. J Allergy Clin Immunol. 1998;102:251-255. ⁴ Data on file at Bausch & Lomb Pharmaceuticals.